By Gilang Cahya 
In the complex landscape of cancer immunology, regulatory T (Treg) cells have long been recognized as a double-edged sword. Typically, their presence in solid tumors is associated with a more aggressive disease and poorer patient prognosis. These crucial immune cells, designed to maintain immune homeostasis and prevent autoimmune reactions, can inadvertently dampen the body’s ability to mount an effective attack against malignant cells. However, colorectal cancer presents a confounding exception to this widely observed phenomenon. For years, researchers have grappled with the paradoxical finding that in colorectal cancer, a higher abundance of Treg cells often correlates with improved patient survival and better outcomes. This divergence from the norm has fueled intensive investigation, seeking to understand the underlying mechanisms that differentiate colorectal cancer’s immune microenvironment.
Now, a groundbreaking study from researchers at the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) offers a compelling and clear explanation for this long-standing enigma. Published in the prestigious scientific journal Immunity, the findings dismantle the notion of Tregs as a monolithic entity, revealing that their functional impact is dictated by distinct subtypes with opposing roles. This discovery not only clarifies the Treg paradox in colorectal cancer but also holds significant promise for refining immunotherapy strategies for a broad spectrum of cancers, potentially including those originating in the skin, stomach, mouth, and throat.
The Dual Nature of Regulatory T Cells in Colorectal Cancer
The cornerstone of this new research lies in the identification of two distinct subtypes of Treg cells within colorectal tumors, each wielding a contrasting influence on tumor progression. "Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explained Alexander Rudensky, PhD, co-senior author of the study and chair of the Immunology Program at MSK. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches."
This revelation challenges the conventional understanding of Treg cells as uniformly immunosuppressive. The MSK team’s meticulous work demonstrates that the mere presence of Tregs is insufficient to predict clinical outcome; it is the specific functional profile of these cells that dictates whether they act as allies or adversaries in the fight against cancer.
A Decades-Long Journey of Discovery
This pivotal breakthrough is the culmination of over two decades of pioneering research by Dr. Rudensky, a globally recognized authority on regulatory T cells. His foundational work established the critical role of Tregs in maintaining "immune tolerance"—the delicate balance that allows the immune system to distinguish between harmful pathogens and harmless entities, thereby preventing assaults on the body’s own tissues, beneficial microbes, and dietary components. Through years of dedicated investigation, Dr. Rudensky’s laboratory has systematically elucidated the intricate mechanisms governing Treg cell development, function, and their complex interplay with cancer.
The current study, led by first authors Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in the lab of computational biologist Christina Leslie, PhD, the study’s other senior author, represents a significant leap forward in this ongoing research narrative. Their collaborative efforts have translated fundamental immunological principles into tangible insights with direct clinical relevance.
Focusing on the Predominant Form of Colorectal Cancer
Colorectal cancer, a significant public health concern, ranks as the second leading cause of cancer-related mortality for both men and women combined, according to the American Cancer Society. The MSK study strategically focused on the most prevalent subtype of colorectal cancer, which accounts for approximately 80% to 85% of all cases. These tumors are characterized by microsatellite stability (MSS) and proficient mismatch repair (MMRp), indicating a relatively stable DNA profile. Crucially, this particular subset of colorectal cancers has historically exhibited a poor response to checkpoint inhibitor immunotherapies, a class of drugs that has revolutionized cancer treatment for other tumor types.
This stands in stark contrast to cancers with high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd). Earlier research conducted at MSK had demonstrated the remarkable efficacy of checkpoint inhibitors against these MSI-H/MMRd tumors, often enabling patients to bypass conventional treatments like surgery, chemotherapy, and radiation. The persistent challenge in treating MSS colorectal cancer has underscored the urgent need for novel therapeutic strategies, making the insights from the current study particularly impactful.
Unveiling the Two Treg Subtypes and Their Mechanisms
To dissect the unique immune environment of MSS colorectal cancer, the research team employed a sophisticated mouse model meticulously engineered to replicate the genetic alterations, behavioral patterns, and immune milieu characteristic of human colorectal tumors. Through rigorous experimentation, they identified two primary categories of tumor-associated Treg cells, differentiated by their production of a key signaling molecule, or cytokine, known as interleukin-10 (IL-10).
The researchers systematically manipulated the presence of each Treg subtype to elucidate their respective impacts on tumor growth. Their findings revealed a clear division of labor:
-
IL-10-Positive Treg Cells: The Tumor Restrainers: This beneficial subtype of Treg cells plays a protective role by suppressing the activity of Th17 cells. Th17 cells, another type of immune cell, produce interleukin 17 (IL-17), a cytokine that acts as a potent growth stimulant for tumors. By dampening Th17 cell activity, IL-10-producing Tregs effectively curb tumor proliferation. These protective cells were predominantly found in the healthy tissue surrounding the tumor. In experiments where these IL-10-positive Tregs were selectively removed, the researchers observed a significant acceleration in tumor growth.
-
IL-10-Negative Treg Cells: The Tumor Fuelers: In stark contrast, the IL-10-negative Treg cells exhibited an immunosuppressive function that directly benefited tumor progression. These cells were found to inhibit potent immune effector cells, most notably CD8+ T cells, which are renowned for their ability to identify and eliminate cancer cells. This detrimental subtype was primarily localized within the tumor microenvironment itself. When these IL-10-negative Tregs were eliminated, the study observed a marked reduction in tumor size.
Validation with Human Patient Data
To solidify their findings, the research team analyzed tumor samples obtained from human colorectal cancer patients. This analysis corroborated the existence of two distinct populations of Treg cells, mirroring the IL-10-positive and IL-10-negative subtypes identified in the mouse model.
Furthermore, a comprehensive analysis of clinical outcomes for over 100 colorectal cancer patients revealed a strong correlation between Treg subtype abundance and patient survival. Patients whose tumors harbored higher levels of the beneficial IL-10-positive Treg cells demonstrated significantly longer survival periods. Conversely, those with a greater prevalence of the detrimental IL-10-negative Treg cells experienced poorer prognoses. "This research shows how important these positive cells are," remarked Dr. Huang. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones."
Targeting CCR8: A Promising Therapeutic Avenue
The identification of these distinct Treg populations opens a promising new chapter in the development of targeted therapies for colorectal cancer. Dr. Rudensky indicated that the IL-10-negative Treg cells, the ones that suppress the anti-tumor immune response and are found within tumors, exhibit high expression levels of a protein known as CCR8.
Intriguingly, prior research originating from Dr. Rudensky’s lab, spearheaded by breast cancer surgeon George Plitas, MD, had already established that CCR8 is also highly expressed on tumor-infiltrating Treg cells in breast cancer and a wide array of other human malignancies. This earlier work suggested that antibodies designed to target CCR8 could be used to selectively deplete these harmful Treg cells, thereby unleashing the body’s immune system to more effectively combat tumors without compromising the function of beneficial Treg cells.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky stated. This strategy holds the potential to rebalance the immune microenvironment, shifting it from a state of immune suppression to one of immune activation.
Indeed, multiple clinical trials are currently underway at MSK and other leading institutions to evaluate the efficacy of CCR8-targeting antibodies. These trials are exploring the use of these antibodies both as monotherapy and in combination with existing immunotherapies. The current study provides compelling evidence to support the application of this strategy in colorectal cancer and potentially expands its utility to other cancer types.
Echoes in Other Cancers: A Shared Immune Pattern
The researchers extended their investigation beyond colorectal cancer, analyzing a substantial dataset of T cells from 16 diverse cancer types. Their objective was to determine if the observed Treg subtype dichotomy was a widespread phenomenon. The results indicated similar distinctions between IL-10-positive and IL-10-negative Treg cells in several cancers affecting barrier tissues, including those of the skin, mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," noted Dr. Mitra, who spearheaded the data analysis for the study. This suggests that therapies designed to selectively eliminate IL-10-negative Tregs in colorectal cancer might also prove effective against these other cancers that arise in tissues with similar immune surveillance functions.
Navigating the Complexity of Metastatic Disease
A critical nuance emerged when the researchers examined colorectal cancer that had disseminated to the liver, a common site for metastasis. In these advanced, metastatic tumors, the immune landscape shifted dramatically. Here, IL-10-negative Treg cells significantly outnumbered their IL-10-positive counterparts. Furthermore, unlike in primary tumors, the complete elimination of all Treg cells in this metastatic context led to a reduction in tumor size.
This finding underscores the intricate and context-dependent nature of the immune response in cancer. It highlights the imperative for treatment strategies to be tailored not only to the specific tissue of origin but also to the stage of the disease, particularly when considering the transition from primary to metastatic disease.
Broader Implications and Future Directions
The implications of this research are far-reaching. By demystifying the Treg paradox in colorectal cancer, the study provides a critical rationale for developing highly selective immunotherapies. The ability to precisely target and eliminate immunosuppressive Treg subtypes while preserving the anti-tumor immune response promises to enhance the efficacy of existing treatments and pave the way for novel therapeutic interventions.
The identification of CCR8 as a key target for selective Treg depletion offers a tangible pathway to clinical translation. As global efforts accelerate to bring Treg-based immunotherapies into the clinic, this MSK study provides robust scientific backing for the CCR8 targeting strategy, particularly within the context of colorectal cancer and other cancers arising in barrier tissues. The ongoing clinical trials represent a crucial next step in translating these groundbreaking discoveries into tangible benefits for patients.
The meticulous work of Huang, Feng, Mitra, Rudensky, Leslie, and their colleagues at MSK represents a significant advancement in our understanding of cancer immunology. It not only resolves a long-standing paradox in colorectal cancer but also offers a beacon of hope for improved therapeutic strategies across a range of difficult-to-treat malignancies. The future of cancer immunotherapy may well lie in precisely orchestrating the complex symphony of immune cells, a feat that this research brings us closer to achieving.
Acknowledgements and Funding
The study involved a multidisciplinary team, with contributions from Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh. The Integrated Genomics Operation and the Single Cell Research Initiative at MSK provided essential support for the research. Funding for this work was generously provided by the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-Josée Kravis Fellowship in Quantitative Biology. Dr. Rudensky has disclosed financial interests and advisory roles with several biotechnology and pharmaceutical companies, including Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, Nilo Therapeutics, Amgen, BioInvent, and Vedanta Biosciences. He has also consulted for AbbVie and serves as an editor for the Journal of Experimental Medicine and an editorial advisor to Immunity. Dr. Rudensky and Dr. Plitas hold patents and patent applications related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8.
